| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
| Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
9 |
19 |
27 |
56 |
| End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-03-02 |
4 |
AS |
$86.12 |
$398,120 |
D/D |
(4,623) |
49,688 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-03-01 |
4 |
AS |
$84.22 |
$842,769 |
D/D |
(10,000) |
340,500 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$3,870,241 |
D/D |
(47,273) |
122,436 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$1,445,497 |
D/D |
(17,656) |
80,366 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-02-29 |
4 |
D |
$81.87 |
$15,799,436 |
D/D |
(192,982) |
350,500 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$3,828,732 |
D/D |
(46,766) |
54,311 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$4,622,708 |
D/D |
(56,464) |
103,919 |
|
- |
|
| Ajer Jeffrey Robert |
SVP, Chief Commercial Officer |
• – – |
2016-02-29 |
4 |
D |
$81.87 |
$1,445,497 |
D/D |
(17,656) |
50,532 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
72,633 |
101,077 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
72,633 |
169,709 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
315,228 |
543,482 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
32,028 |
98,022 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
87,537 |
160,383 |
|
- |
|
| Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
32,583 |
68,188 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2016-02-22 |
4 |
AS |
$80.00 |
$600,000 |
D/D |
(7,500) |
26,250 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2016-02-22 |
4 |
OE |
$38.59 |
$289,425 |
D/D |
7,500 |
33,750 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-01-07 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,675 |
34,351 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2016-01-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,675 |
119,761 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2016-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,100 |
2,100 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2015-12-16 |
4 |
AS |
$100.00 |
$136,200 |
D/D |
(1,362) |
66,156 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2015-11-30 |
4 |
AS |
$94.74 |
$94,744 |
I/I |
(1,000) |
25,758 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2015-11-16 |
4 |
S |
$107.27 |
$804,530 |
D/D |
(7,500) |
11,850 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2015-11-16 |
4 |
OE |
$17.33 |
$129,975 |
D/D |
7,500 |
19,350 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2015-11-16 |
4 |
AS |
$104.26 |
$109,468 |
D/D |
(1,050) |
11,850 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2015-11-16 |
4 |
AS |
$104.27 |
$782,054 |
D/D |
(7,500) |
26,250 |
|
- |
|
1285 Records found
|
|
Page 44 of 52 |
|
|
1.44 (1.6%) 
